We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PhoreMost Awarded £1.4M Innovate UK Funding
News

PhoreMost Awarded £1.4M Innovate UK Funding

PhoreMost Awarded £1.4M Innovate UK Funding
News

PhoreMost Awarded £1.4M Innovate UK Funding

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PhoreMost Awarded £1.4M Innovate UK Funding"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PhoreMost Ltd has announced that it has been selected to receive a funding award of £1.4M (approximately $2.14M USD) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers.

Based on PhoreMost’s proprietary Protein Interference technology, the Company has developed ‘Site-Seeker’, a next-generation phenotypic screening platform that can identify the best new targets for drug development and, crucially, how to drug them.

PhoreMost’s lead therapeutic programme has identified drug candidates to a novel synthetic-lethal target for KRAS. The Innovate UK funding will support development of this programme through phases of lead optimization and candidate selection, with a longer aim to create a drug that may be tested in human clinical trials.

“We are pleased to receive funding from Innovate UK in support of our lead programme,” commented Dr Chris Torrance, CEO of PhoreMost. “The expert reviews conducted by Innovate UK provide independent, competitive validation of our lead programme development strategy, and the award funds will support our business aims to create novel therapies for cancer patients who have limited treatment options.”

KRAS is one of the most commonly mutated genes in cancer: it drives disease initiation and progression, and is frequently a secondary event in ‘acquired’ resistance to new targeted therapies.

However, KRAS mutant cancers remain largely unaffected by the development of new targeted therapies. Each year, cancers with RAS mutations account for approximately 25,000 deaths in the UK and 120,000 in the U.S.

Advertisement